Effects of chronic administration of interferon α A/D on serotonergic receptors in rat brain

Neurochemical Research

Volumn 24, Issue 3, 1999, Pages 359-363

  Abe, Shuzo ^a   Hori, Takafumi ^a   Suzuki, Toshihito ^a   Baba, Atsuomi ^a   Shiraishi, Hiroyasu ^a   Yamamoto, Toshifumi ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

5 HT7; Depression; Interferon; Neuropsychiatric complications; Serotonin

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ALPHA INTERFERON; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; DEPRESSION; MALE; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SCATCHARD PLOT; SEROTONIN BRAIN LEVEL;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BRAIN; CARRIER PROTEINS; CELL MEMBRANE; CEREBRAL CORTEX; HIPPOCAMPUS; INTERFERON TYPE I, RECOMBINANT; KETANSERIN; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PAROXETINE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TRITIUM;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0032956183     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020929415443     Document Type: Article

References (38)

1. Renault, R. P., Hoognagle, J. H., Park, Y., Mullen, K. D., Peters, M., Jones, B., Rustgi, V., and Jones, A. 1987. Psychiatric complications of long-term interferon alpha therapy. Arch. Intern. Med. 147:1577-1580.
2. McDonald, E. M., Mann, A. H., and Thomas, H. C. 1987. Interferon as mediators of psychiatric morbidity. Lancet, 21:1175-1178.
3. Levenson, J. A., and Fallon, H. J. 1993. Fluoxetine treatment of depression caused by interferon-α. Am. J. Gastroenter., 88:760-761.
4. Roosth, J., Richard, B., Pollard, S., Brown, L. and Meyer, W. J. 1986. Cortisol stimulation by recombinant interferon- α2. J. Neuroimm., 12:311-316.
5. Meyers, C. A., Scheibel, R. S., and Forman, A. D. 1991. Persistent neurotoxicity of systemically administrated interferon-alpha. Neurology, 41:672-676.
6. Müller, H., Hammes, E, Hiemke, C., and Hess, G. 1991. interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man. Neuroendocrinology, 54:499-503.
7. Kidron, D., Saphier, D., Ovadia, H., Weidenfireld, J., and Abramsky, O. 1989. Central administration of immunomodulatory factors alters neural activity and adrenocortical secretion. Brain Behav. Immun. 3:15-27.
8. Segall, M. A., and Crnic, L. S. 1990. An animal model for the behavioral effects of interferon. Behav. Neurosci., 104:612-618.
9. Dunn, A. L., and Crnic, L. S. 1993. Repeated injection of interferon-αA/D in Balb/c mice: behavioral effects. Brain Behav. Immun., 7:104-111.
10. Saphier, D., Welch, J. E., and Chuluyan, H. E. 1993. α-Interferon inhibits adrenocortical secretion via μ1-Opioid receptors in the rat. Eur. J. Pharmacol., 236:183-191.
11. Saphier, D., Roerig, S. C., Ito, C., Vlasak, W. R., Farrar, G. E., Broyles, J. E., and Welch, J. E. 1994. Inhibition of neural and neuroendocrine activity by α-interferon: neuroendocrine, electrophysiological, and biochemical studies in the rat. Brain Behav. Immun., 8:37-56.
12. Farkkila, M., Iivanainen, M., Harkonen, M., Laakso, J., Mattson, K., Niiranen, A., Larson, T. A., and Cantell, K. 1988. Effect of interferon-γ on biogenic amine metabolism, electroencephalographic recordings, and transient potentials. Clin. Neuropharm. 11: 63-67.
13. Habif, D. V., Lipton, R. and Cantell, K. 1975. Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc. Soc. Exp. Biol. Med., 149:287-289.
14. Greig, N. H., Soncrant, T. T., Wozniak, K. M. and Rapoport, S. I. 1988. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration. J. Pharmacol. Exp. Ther., 245:574-580.
15. Wiranowska, M., Wilson, T. C., Thompson, K. and Prockop, L. D. 1989. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J. Interferon Res., 9:353-362.
16. Janicki P. K. 1992. Binding of human alpha-interferon in the brain tissue membranes of rat. Res. Commun. Chem. Pathol. Pharmacol., 75:117-120.
17. Menzies, R. A., Patel, R., Hall, N. R. S., O'Grady, M. P., and Rier, S. E. 1992. Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci. 50:227-232.
18. Pazos, A., Hoyer, D., and Palacios, J. M. 1984. Mesulergine, a selective serotonin-2 ligand in the rat cortex: evidence for species differences in brain serotonin-2 receptors. Eur. J. Pharmacol. 106: 531-538.
19. 3H]8-Hydroxy-2-(Di-n-Propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. J. Neurochem., 44:1685-1696.
20. 3H]paroxetine binding to rat cortical membranes. Eur. J. Pharmacol., 118:107-114.
21. Lowry, O. H., Rosenbough, M. J., Farr, A. C., and Randell, R.J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193:265-275.
22. Munson, P. J. and Rodbard, D. 1980. LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal. Biochem., 107:220-239.
23. Goodnough, D. B., and Baker, G. B. 1994. 5-Hydrotryptamine 2 and β-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem., 62:2262-2268.
24. 3H]-paroxetine binding to the 5-HT uptake site in rat cortical membranes. Psychopharmacology, 95:68-70.
25. Sprouse, J. S., Aghajanian, G. K. 1987. Electrophysiological response of serotonergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonist. Synapse, 1:3-9.
26. 3H]hydroxydipropylaminotetralin. J. Neurochem., 62:1822-1834.
27. 7) implicated in the regulation of mammalian circadian rhythms. Neuron, 11:449-458.
28. 7) activating cAMP formation. Proc. Natl. Acad. Sci. USA, 90:8547-51.
29. Hrdina, P. D., Demeter, E., Vu, T. B., Sotonyi, P., and Palkovits, M. 1993. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res., 614:37-44.
30. Pacheco, M. A., Stockmeier, C., Meltzer, H. Y., Overholser, J. C., Dilley, G. E., and Jope, R. S. 1996. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res., 723:37-45.
31. Brunner, J. D., Innis, R. B., Salomon, R. M., Staib, L. H., Ng, C. K., Miller, H. L., Bronen, R. A., krystal J. H., Duncan, J., Rich, D., Price, L. H., Malison, R., Dey, H., Soufer, R., and Charney, D. S. 1997. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch. Gen. Psychiatry, 54:364-374.
32. Gustafson, E. L., Durkin, M. M., Bard, J. A., Zgombick, J. and Branchek, T. A. 1996. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain. Br. J. Pharmacol., 117:657-666.
33. Shimizu, S., Nishida, A., Zensho, H. and Yamawaki, S. 1996. Chronic antidepressants exposure enhances 5-hydroxytryptamine7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. J. Pharmacol. Exp. Ther., 279: 1551-1558.
34. Roth, B. L., Craigo, S. C., Choudhary, M. S., Uluer, A., Monsma, F. J. Jr., Shen, Y., Meltzer, H. Y., Sibley, D. R. 1994. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther., 268:1403-1410.
35. D'Urso, R., Falaschi, P., Canfalone, G., Carusi, E., Proietti, A., Barnaba, V., and Balsano, F. 1991. Neuroendocrine effects of recombinant α-interferon administration in humans. Prog. Neuroendocrin Immunonol., 4:20-25.
36. Kathol, R. G., Jaeckle, R. S., Lopez, J. F., and Meller, W. H. 1989. Pathophysiology of HPA axis abnormalities in patients with major depression: an update. Am. J. Psychiatry, 146:311-317.
37. 1A(serotonin-1A) receptor mRNA expression in rat hippocampus after adrenalectomy. Psychopharmacology, 130:368-374.
38. 7 receptor gene expression in the rat hippocampus. Mol. Brain Res., 45:182-186.